Edgar Filing: Quisel John D - Form 4

| Quisel John Form 4 | | | | | | | | | | | | |
|---|----------------------|---|---|--------------|------------|------------------|--------------------|---|--|-------------------------|--|--|
| April 04, 20 | 18 | | | | | | | | | | | |
| FORM | | | CECUE | | | PROVAL | | | | | | |
| | UNITED | STATES | | shington, | | | NGE C | OMMISSION | OMB Number: | 3235-0287 January 31 | | |
| Check th if no long subject to Section 1 Form 4 c | statem STATEM | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | | | | | | | | | | |
| Form 5 obligatio may com <i>See</i> Instr 1(b). | ns Section 17(a | | | | | | | | | | | |
| (Print or Type] | Responses) | | | | | | | | | | | |
| | | | 2. Issuer Name and Ticker or Trading Symbol ACCELERON PHARMA INC [XLRN] | | | | | 5. Relationship of Reporting Person(s) to Issuer | | | | |
| | | | | | | | | (Check all applicable) | | | | |
| 128 SIDNEY STREET (C (Street) 4 | | | 3. Date of Earliest Transaction (Month/Day/Year) 04/03/2018 | | | | | Director 10% Owner X Officer (give title Other (specify below) below) SVP, Corp. Dev., GC & Sec. | | | | |
| | | | 4. If Amendment, Date OriginalFiled(Month/Day/Year) | | | | | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person | | | | |
| CAMBRID | GE, MA 02139 | | | | | | | Form filed by M Person | | | | |
| (City) | (State) | (Zip) | Tabl | e I - Non-E | Derivative | Secur | ities Acq | uired, Disposed of | , or Beneficial | ly Owned | | |
| 1.Title of Security (Instr. 3) | any | | ned n Date, if Day/Year) | | | | | Securities Beneficially Owned | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | | |
| | | | | Code V | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | | | |
| Common Stock | 04/03/2018 | | | S <u>(1)</u> | 1,104 | D | \$ 38.33 (2) | 56,698 | D | | | |
| Common Stock | 04/03/2018 | | | S <u>(1)</u> | 100 | D | \$ 39.16 | 56,598 | D | | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Quisel John D - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transacti Code (Instr. 8) | 5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | | ate | Amou Unde Secur | le and unt of rlying tities . 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr |
|---|---|---|---|---------------------------------------|---|---------------------|--------------------|-----------------------|--|---|---|
| | | | | Code V | (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | |

Reporting Owners

| Reporting Owner Name / Addres | s | Relationships | | | | | | | |
|---|------------|---------------|----------------------------|-------|--|--|--|--|--|
| | Director | 10% Owner | Officer | Other | | | | | |
| Quisel John D 128 SIDNEY STREET CAMBRIDGE, MA 02139 | | | SVP, Corp. Dev., GC & Sec. | | | | | | |
| Signatures | | | | | | | | | |
| /s/ John D. | 04/04/2010 | | | | | | | | |

04/04/2018 Quisel **Signature of Date

Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$37.90 to \$38.89 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or (2) the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.